Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in …
SHI Ou, CH Bartlett, M Mino-Kenudson, J Cui… - The …, 2012 - academic.oup.com
Abstract Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the US Food and Drug
Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small …
Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small …
Recurrent oral cancer: current and emerging therapeutic approaches
SD da Silva, M Hier, A Mlynarek, LP Kowalski… - Frontiers in …, 2012 - frontiersin.org
Oral cavity cancer (OCC) is associated with high incidence of loco-regional recurrences,
which account for the majority of treatment failures post-surgery and radiotherapy. The time …
which account for the majority of treatment failures post-surgery and radiotherapy. The time …
[HTML][HTML] Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer
AJ Weickhardt, B Scheier, JM Burke, G Gan… - Journal of Thoracic …, 2012 - Elsevier
Introduction: Many patients with oncogene-driven non–small-cell lung cancer (NSCLC)
treated with tyrosine kinase inhibitors experience limited sites of disease progression. This …
treated with tyrosine kinase inhibitors experience limited sites of disease progression. This …
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Peters, AA Adjei, C Gridelli, M Reck… - Annals of …, 2012 - annalsofoncology.org
Primary lung cancer is the most common malignancy after non-melanocytic skin cancer, and
the leading cause of human cancer deaths worldwide [1]. While it has been the most …
the leading cause of human cancer deaths worldwide [1]. While it has been the most …
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
JCH Yang, JY Shih, WC Su, TC Hsia, CM Tsai… - The lancet …, 2012 - thelancet.com
Background Afatinib is an irreversible ErbB-family blocker with preclinical activity in non-
small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of …
small-cell lung cancer (NSCLC) with EGFR mutations. We aimed to assess the efficacy of …
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors is limited
by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is …
by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is …
[PDF][PDF] First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts… - J Clin Oncol, 2012 - academia.edu
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
[HTML][HTML] Influence of chemotherapy on EGFR mutation status among patients with non–small-cell lung cancer
Purpose EGFR mutation is a predictor of epidermal growth factor receptor–tyrosine kinase
inhibitor treatment response in patients with non–small-cell lung cancer (NSCLC). However …
inhibitor treatment response in patients with non–small-cell lung cancer (NSCLC). However …
[HTML][HTML] Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib
Background: EGFR and KRAS mutations are mutually exclusive and predict outcomes with
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in patients …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in patients …
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
SM Lee, I Khan, S Upadhyay, C Lewanski… - The lancet …, 2012 - thelancet.com
Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …
active supportive care because of poor performance status or presence of several …